The Drug Development Shared Resource provides essential services for Purdue Cancer Center investigators whose research focuses on the design, synthesis and evaluation of novel anticancer agents. The need for a highly integrated in vitro and in vivo drug evaluation service for candidate drugs mandated the creation of this Shared Resource from two previously separate facilities (Cytotoxicity and Athymic Mouse). The Drug Development Shared Resource will provide investigators with the in vitro assays, in vivo xenograft models, pharmacokinetics expertise, and pathology support needed to conduct a rational evaluation of new drugs. Human tumor cell lines of many histologic types will be available for use; a standard panel will be available for drug candidates where the mechanism of action is unknown, but mechanistic information will be used to select cell lines for specific targeted drug candidates. The majority of these cell lines will also be available as xenografts so that promising candidates in vitro can be carried forward directly into in vivo models. Most drug evaluations in vivo will rely on standard subcutaneous xenograft models; unique metastatic xenograft models are also available in the Shared Resource. Facility staff will work with investigators to select appropriate in vitro and in vivo models, drug vehicle, and administration schedule. Expertise in pharmacokinetics and experimental pathology is available to assist in study design and evaluation of tumor response. Ultimately, the goal of the Drug Development Shared Resource is to provide the essential expertise, services and data needed to move promising drug candidates toward further preclinical development in preparation for clinical evaluation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA023168-22
Application #
6344713
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2000-08-17
Project End
2001-06-30
Budget Start
Budget End
Support Year
22
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Purdue University
Department
Type
DUNS #
072051394
City
West Lafayette
State
IN
Country
United States
Zip Code
47907
Chambers, Andrea M; Wang, Jiao; Lupo, Kyle B et al. (2018) Adenosinergic Signaling Alters Natural Killer Cell Functional Responses. Front Immunol 9:2533
Norvil, Allison B; Petell, Christopher J; Alabdi, Lama et al. (2018) Dnmt3b Methylates DNA by a Noncooperative Mechanism, and Its Activity Is Unaffected by Manipulations at the Predicted Dimer Interface. Biochemistry 57:4312-4324
Wu, Heng; Post, Carol Beth (2018) Protein Conformational Transitions from All-Atom Adaptively Biased Path Optimization. J Chem Theory Comput 14:5372-5382
Serratore, Nina D; Baker, Kortany M; Macadlo, Lauren A et al. (2018) A Novel Sterol-Signaling Pathway Governs Azole Antifungal Drug Resistance and Hypoxic Gene Repression in Saccharomyces cerevisiae. Genetics 208:1037-1055
Liu, Wenting; Zhong, Yi-Fang; Liu, Liu-Yi et al. (2018) Solution structures of multiple G-quadruplex complexes induced by a platinum(II)-based tripod reveal dynamic binding. Nat Commun 9:3496
Denton, Kyle E; Wang, Sijie; Gignac, Michael C et al. (2018) Robustness of In Vitro Selection Assays of DNA-Encoded Peptidomimetic Ligands to CBX7 and CBX8. SLAS Discov 23:417-428
Kong, Yifan; Cheng, Lijun; Mao, Fengyi et al. (2018) Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC). J Biol Chem 293:14328-14341
Filley, Anna; Henriquez, Mario; Bhowmik, Tanmoy et al. (2018) Immunologic and gene expression profiles of spontaneous canine oligodendrogliomas. J Neurooncol 137:469-479
Jakubison, Brad L; Schweickert, Patrick G; Moser, Sarah E et al. (2018) Induced PTF1a expression in pancreatic ductal adenocarcinoma cells activates acinar gene networks, reduces tumorigenic properties, and sensitizes cells to gemcitabine treatment. Mol Oncol 12:1104-1124
Ali, Remah; Brown, Wells; Purdy, Stephen Connor et al. (2018) Biased signaling downstream of epidermal growth factor receptor regulates proliferative versus apoptotic response to ligand. Cell Death Dis 9:976

Showing the most recent 10 out of 436 publications